Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081047 | SCV000112954 | benign | not specified | 2013-03-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002311608 | SCV000846410 | benign | Inborn genetic diseases | 2016-04-18 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000870669 | SCV001012194 | benign | Rubinstein-Taybi syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001682774 | SCV001901270 | benign | not provided | 2018-08-21 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002504996 | SCV002801168 | likely benign | Rubinstein-Taybi syndrome due to CREBBP mutations; Menke-Hennekam syndrome 1 | 2022-04-21 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001682774 | SCV005295933 | benign | not provided | criteria provided, single submitter | not provided | ||
ITMI | RCV000081047 | SCV000084753 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |